 |
| 28-Jan-10 | Reiterated |
RBC Capital Mkts |
Top Pick |
$62 → $68 |
|
| 14-Jan-10 | Reiterated |
Barclays Capital |
Overweight |
$56 → $60 |
|
| 12-Nov-09 | Initiated |
Wedbush Morgan |
Outperform |
$62 |
|
| 29-Sep-09 | Reiterated |
UBS |
Buy |
$52 → $55 |
|
| 13-Aug-09 | Upgrade |
Hilliard Lyons |
Long-term Buy → Buy |
|
|
| 16-Jul-09 | Reiterated |
Credit Suisse |
Neutral |
$46 → $47 |
|
| 10-Jul-09 | Reiterated |
Barclays Capital |
Overweight |
$59 → $56 |
|
| 17-Apr-09 | Reiterated |
Argus |
Buy |
$65 → $58 |
|
| 16-Apr-09 | Reiterated |
Credit Suisse |
Neutral |
$54 → $49 |
|
| 09-Apr-09 | Reiterated |
Barclays Capital |
Overweight |
$65 → $59 |
|
| 02-Apr-09 | Upgrade |
Citigroup |
Sell → Hold |
$48 |
|
| 26-Feb-09 | Initiated |
RBC Capital Mkts |
Top Pick |
|
|
| 01-Dec-08 | Reiterated |
Leerink Swann |
Outperform |
$70 → $60 |
|
| 17-Jul-08 | Reiterated |
UBS |
Buy |
$61 → $64 |
|
| 23-Jun-08 | Initiated |
Leerink Swann |
Outperform |
$65 |
|
| 09-May-08 | Initiated |
UBS |
Buy |
$61 |
|
| 20-Mar-08 | Upgrade |
Wachovia |
Mkt Perform → Outperform |
|
|
| 24-Jan-08 | Reiterated |
RBC Capital Mkts |
Top Pick |
$64 → $66 |
|
| 11-Oct-07 | Downgrade |
Wachovia |
Outperform → Mkt Perform |
|
|
| 09-Oct-07 | Initiated |
Stanford Research |
Buy |
|
|
|
|
| 09-Feb-10 08:08AM | Health Care: Rx for MBA Job Blues BusinessWeek |
| 08-Feb-10 02:58PM | CORRECTED - EU expected to clear Abbott, Solvay deal - sources at Reuters |
| 11:14AM | EU expected to clear Abbott, Solvay deal - sources at Reuters |
| 10:28AM | Traders Send Select Stem Cell Shares Soaring Indie Research |
| 09:31AM | InPlay: Abbott Labs submits new automated ovarian cancer test for U.S. approval Briefing.com |
| 09:30AM | Abbott Submits New Automated Ovarian Cancer Test for U.S. Approval PR Newswire |
| 05-Feb-10 04:30PM | [video] CNBC.com Market Outlook at CNBC |
| 07:00AM | Four Cheap Stocks with Solid Earnings Morningstar.com |
| 04-Feb-10 09:10PM | Allergan's Looking Real Pretty Right Now at CNBC |
| 07:43PM | Test of "artificial pancreas" offers diabetes hope at Reuters |
| 03:45PM | Two Pharmas at Forbes.com |
| 02:52PM | Buy These 4 High-Quality Large Caps: Chief Investor at CNBC |
| 10:16AM | 4-Star Stocks Poised to Pop: Myriad Genetics at Motley Fool |
| 12:55AM | 3 Simple Keys to Dividend Investing at Seeking Alpha |
| 03-Feb-10 08:00PM | Ten Questions About High Cholesterol at Forbes.com |
| 01:41PM | Pfizer's Hedge Pays Off at Motley Fool |
| 06:54AM | Acquisitions In Home Health Care And Medical Diagnostics Sector Will Rise In 2010 According To RBC Capital Markets Expert Equity Analyst: Strong Cash Flow And Personalized Medicine Are Drivers Wall Street Transcript |
| 02-Feb-10 06:00PM | Ten Misleading Drug Ads at Forbes.com |
| 05:07PM | Former Wyeth CEO: Pharma Chiefs Face 'More Punishing' Environment at The Wall Street Journal Online |
| 03:54PM | Defense! Defense! at Motley Fool |
| 03:44PM | Shaking Up the Biotech Industry at Motley Fool |
| 02:24PM | Fourth Quarter Trends for Big Pharma at Seeking Alpha |
| 02:16PM | Foolish Forecast: First Look at Pfizer Plus at Motley Fool |
| 01:11PM | Haemonetics Misses Zacks Estimate Zacks.com |
| 11:44AM | Shares of Vaccine Makers up on Lancet Retraction at Fox Business |
| 09:32AM | Becton Stays Neutral Zacks.com |
| 01-Feb-10 11:11PM | [$$] Boston Scientific to Pay J&J $1.73B to Settle Stent Patent Disputes at The Wall Street Journal Online |
| 04:11PM | Now That's Some Expensive Risk Mitigation at Motley Fool |
| 03:08PM | Boston Sci to pay J&J $1.73 billion in settlement Reuters |
| 03:05PM | UPDATE - Boston Sci to pay J&J $1.73 bln in settlement at Reuters |
| 01:38PM | $1.7 Billion Settlement Tops J&J's 2009 Sales of Coated Stents at The Wall Street Journal Online |
| 01:03PM | UPDATE - Boston Sci to pay J&J $1.73 bln in settlement at Reuters |
| 11:47AM | [$$] Boston Scientific To Pay J&J $1.73B To Settle Stent Patent Disputes at The Wall Street Journal Online |
| 10:59AM | Abbott and Pierre Fabre SA Announce Collaboration to Research and Develop Novel Treatments for Cancer PR Newswire |
| 09:30AM | Boston Sci Pays J&J $1.7B to End Stent Patent Dispute at Barrons.com |
| 05:00AM | Health Bills Target Tanning, Snack Machines TheStreet.com |
| 31-Jan-10 06:43AM | How We Decide What Stocks to Buy at Seeking Alpha |
| 30-Jan-10 09:35AM | David B. Snow, Jr. MedcoHealth Solutions (MHS) CEO And Chairman Of The Board Interview With The Wall Street Transcript Wall Street Transcript |
| 29-Jan-10 07:48AM | BG Medicine plans IPO for $86.3 million AP |
| 05:47AM | Cramer's Mad Money - The World's Biggest Supermarket of Tech (1/28/10) at Seeking Alpha |
| 28-Jan-10 07:35PM | A Greek Tragedy? at CNBC |
| 04:51PM | [$$] Abbott Labs Profit Flat Despite 11% Revenue Growth at The Wall Street Journal Online |
| 03:29PM | The Biggest Development-Stage Drugmaker, Ever at Motley Fool |
| 03:24PM | Pharma & Biotech Stock Review Zacks.com |
| 10:09AM | How to Make a Billion Bucks in Biotech at Motley Fool |
| 09:24AM | New Star Analyst Rankings for ABBOTT LABORATORIES StarMine |
| 08:31AM | Becton Surpasses Zacks Estimate Zacks.com |
| 27-Jan-10 05:11PM | Stocks Eke Out Gain as Financials Rebound at CNBC |
| 05:02PM | Stocks Advance as Fed Soothes at TheStreet.com |
| 04:48PM | Abbott Laboratories Q4 2009 Earnings Call Transcript at Seeking Alpha |
| 04:21PM | Humira or Not, Abbott's on a Roll at Motley Fool |
| 04:03PM | Stocks Gain as Fed Soothes at TheStreet.com |
| 03:24PM | Biotech Stocks: Gilead gains, Abbott slides on quarterly reports at MarketWatch |
| 03:02PM | UPDATE - Abbott sales jump, but Humira sales weigh on stock at Reuters |
| 02:58PM | Stocks Gain as Rates Stay Same at TheStreet.com |
| 02:53PM | [$$] Wait to Build Positions in IHE at RealMoney by TheStreet.com |
| 02:32PM | Stocks Slide After Fed Non-Statement CNBC |
| 02:07PM | Diagnostic Companies Are Becoming "Quasi-Device" Research And Development Businesses As Life Sciences Innovations Continue Wall Street Transcript |
| 02:06PM | Stocks Slip Ahead of Fed Statement; Apple Falls at CNBC |
| 01:32PM | Selling a Health Business in the Developing World? Call Abbott at The Wall Street Journal Online |
| 12:58PM | A Good Start To Earnings Season? at Investopedia |
| 12:52PM | Stocks Lower Ahead of Fed, Obama at TheStreet.com |
| 12:17PM | Abbott Laboratories profit stays flat in 4Q AP |
| 11:54AM | RPT-UPDATE - Abbott sales jump, but Humira sales weigh on stock at Reuters |
| 11:45AM | Abbott profit flat due to charges; sales up 11% at MarketWatch |
| 11:22AM | On the Call: Abbott Laboratories AP |
| 11:15AM | [$$] Abbott Sells Off on Quirky Guidance at RealMoney by TheStreet.com |
| 11:04AM | Stocks Mixed After Weak Housing Data at TheStreet.com |
| 10:17AM | Stocks Slide as AIG Hearing Begins; Ford Gains at CNBC |
| 10:12AM | Abbott Beats, Guides Higher Zacks.com |
| 09:54AM | Stocks Flat Ahead of Fed Statement at TheStreet.com |
| 09:25AM | RPT-UPDATE - Abbott sales jump, but Humira sales weigh on stock at Reuters |
| 09:06AM | Companion Diagnostics Creates New Sector For Testing Pharmaceutical Efficacy: High Growth Rates Seen For KRAS Mutation Testing As Predictive Biomarker For EGFR Inhibitors Wall Street Transcript |
| 09:00AM | Abbott Earnings Call scheduled for 9:00 am ET today CCBN |
| 08:53AM | Abbott Labs posts fourth-quarter profit at MarketWatch |
| 08:37AM | ABBOTT LABORATORIES Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhib EDGAR Online |
| 08:11AM | UPDATE - Abbott sales surge, 2010 view tops forecasts at Reuters |
| 07:52AM | Futures Point Higher Ahead of Fed Statement at TheStreet.com |
| 07:46AM | Abbott Reports Double-Digit Sales and Earnings Growth in Fourth Quarter; Issues Strong Earnings Outlook for 2010 PR Newswire |
| 07:32AM | Futures Edge Higher; Ford Gains, Toyota Falls at CNBC |
| 07:07AM | Q4 2009 Abbott Earnings Release - Before Market Open CCBN |
| 26-Jan-10 07:43PM | Stocks to Watch: Stocks in focus for Wednesday at MarketWatch |
| 05:42PM | Earnings Roundup: Jan. 27 at CNBC |
| 04:32PM | Is the Best of Johnson & Johnson Behind It? at Motley Fool |
| 03:39PM | Timing Is Everything for Amgen at Motley Fool |
| 03:05PM | Don't blame us, pallet industry tells tainted Tylenol maker at CNNMoney.com |
| 01:02PM | TradingMarkets 7 Stocks You Need to Know for Wednesday TradingMarkets.com |
| 12:54PM | Calendar of business events set for Wednesday AP |
| 11:46AM | Earnings Preview: Abbott Labs at Seeking Alpha |
| 11:27AM | [$$] ABT Preview: Defensive Stocks Back in Vogue? at RealMoney by TheStreet.com |
| 10:07AM | A Big Upgrade for Cepheid at Motley Fool |
| 09:33AM | Brown's Win Boosts Healthcare Stocks at Seeking Alpha |
| 01:00AM | Dividend Attraction Zacks.com |
| 25-Jan-10 11:30PM | Bringing Atkins Back From The Dead at Forbes.com |
| 04:08PM | Abbott's Many Trials at Forbes.com |
| 03:29PM | Obamacare FAIL: The One Stock to Buy at Motley Fool |
| 11:39AM | Earnings Preview: Abbott Laboratories to report 4Q AP |
| 10:34AM | 3 Reasons to Buy Geron Today at Motley Fool |
| 10:33AM | 3 Reasons to Sell Geron Today at Motley Fool |
| 10:27AM | Abbott sues Teva over Simcor patents at Reuters |
|
|
| Abbott Laboratories manufactures and sells health care products worldwide. The company's Pharmaceutical Products segment offers adult and pediatric pharmaceuticals for rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, psoriasis, Crohn's disease, dyslipidemia, HIV infection, hypothyroidism, advanced prostate cancer, endometriosis and central precocious puberty, anemia caused by uterine fibroids, obesity, epilepsy and bipolar disorder, migraines, and secondary hyperparathyroidism; and provides anesthesia products and anti-infectives. Its Diagnostic Products segment offers immunoassay systems; chemistry systems; assays used for screening and/or diagnosis for drugs of abuse, cancer, therapeutic drug monitoring, fertility, physiological diseases, and infectious diseases; instruments that automate the extraction, purification, and preparation of DNA and RNA from patient samples, and detect and measure infections agents; genomic-based tests; hematology systems and reagents; and point-of-care diagnostic systems and tests for blood analysis. The company's Nutritional Products segment provides various forms of prepared infant formula and follow-on formula, adult and other pediatric nutritional products, nutritional products used in enteral feeding in health care institutions, and bars and nutritional brands. Its Vascular Products segment offers coronary, endovascular, and vessel closure devices, such as drug-eluting coronary stent systems, coronary metallic stents, balloon dilatation products, coronary guidewires, vessel closure devices, and carotid stent systems to treat vascular disease. Abbott serves wholesalers, government agencies, health care facilities, specialty pharmacies, independent retailers, hospitals, clinics, physicians' offices, blood banks, commercial laboratories, alternate-care testing sites, plasma protein therapeutic companies, and third-party distributors. The company was founded in 1888 and is based in Abbott Park, Illinois. |
|
| Insider Trading |
Relationship |
Date |
Transaction |
Cost |
#Shares |
Value ($) |
#Shares Total |
SEC Form 4 |
| FREYMAN THOMAS C | Executive Vice President | Feb 10 | Sale | 53.36 | 1,500 | 80,040 | 343,215 | Feb 03 06:18 PM | | FULLER H LAURANCE | Director | Feb 02 | Option Exercise | 35.92 | 5,678 | 203,949 | 21,006 | Feb 04 06:24 PM | | FULLER H LAURANCE | Director | Feb 02 | Sale | 54.40 | 5,678 | 308,896 | 15,328 | Feb 04 06:24 PM | | FREYMAN THOMAS C | Executive Vice President | Feb 01 | Sale | 53.35 | 23,500 | 1,253,621 | 337,515 | Feb 03 06:18 PM | | LIEPMANN HOLGER A | Executive Vice President | Dec 29 | Option Exercise | 53.40 | 7,530 | 402,102 | 162,872 | Dec 30 05:17 PM | | LIEPMANN HOLGER A | Executive Vice President | Dec 29 | Sale | 54.75 | 7,530 | 412,268 | 155,342 | Dec 30 05:17 PM | | Warmuth Michael J | Senior Vice President | Dec 28 | Option Exercise | 54.05 | 1,849 | 99,938 | 72,422 | Dec 29 06:06 PM | | Warmuth Michael J | Senior Vice President | Dec 28 | Sale | 54.50 | 1,849 | 100,771 | 70,573 | Dec 29 06:06 PM | | SMITHBURG WILLIAM D | Director | Dec 24 | Option Exercise | 42.73 | 6,177 | 263,961 | 57,448 | Dec 28 06:28 PM | | SMITHBURG WILLIAM D | Director | Dec 23 | Option Exercise | 35.92 | 5,678 | 203,949 | 56,949 | Dec 28 06:28 PM | | SMITHBURG WILLIAM D | Director | Dec 23 | Sale | 53.98 | 5,678 | 306,505 | 51,271 | Dec 28 06:28 PM | | LINDER GREG W | Vice President | Dec 22 | Option Exercise | 51.09 | 30,308 | 1,548,387 | 197,146 | Dec 23 07:18 PM | | Hance Robert B | Senior Vice President | Dec 22 | Option Exercise | 44.34 | 61,125 | 2,710,007 | 196,619 | Dec 23 07:30 PM | | WHITE MILES D | Chairman and CEO | Dec 22 | Option Exercise | 47.69 | 172,704 | 8,237,016 | 1,411,423 | Dec 23 07:48 PM | | WHITE MILES D | Chairman and CEO | Dec 22 | Sale | 54.21 | 172,704 | 9,362,673 | 1,238,719 | Dec 23 07:48 PM | | Hance Robert B | Senior Vice President | Dec 22 | Sale | 54.10 | 18,564 | 1,004,367 | 178,055 | Dec 23 07:30 PM | | LINDER GREG W | Vice President | Dec 22 | Sale | 54.14 | 30,308 | 1,640,760 | 166,838 | Dec 23 07:18 PM | | Chen Thomas F | Senior Vice President | Dec 18 | Sale | 53.71 | 7,800 | 418,938 | 88,764 | Dec 18 06:35 PM | | LIEPMANN HOLGER A | Executive Vice President | Dec 10 | Option Exercise | 52.25 | 3,865 | 201,957 | 159,207 | Dec 11 06:51 PM | | Patton Donald V JR | Senior Vice President | Dec 10 | Option Exercise | 52.75 | 9,875 | 520,906 | 92,660 | Dec 11 05:55 PM | | Patton Donald V JR | Senior Vice President | Dec 10 | Sale | 54.01 | 9,875 | 533,359 | 82,785 | Dec 11 05:55 PM | | Chen Thomas F | Senior Vice President | Dec 10 | Sale | 53.80 | 5,000 | 269,000 | 96,564 | Dec 11 05:50 PM | | LIEPMANN HOLGER A | Executive Vice President | Dec 10 | Sale | 54.25 | 3,865 | 209,677 | 155,342 | Dec 11 06:51 PM | | LIEPMANN HOLGER A | Executive Vice President | Dec 07 | Option Exercise | 52.25 | 100 | 5,225 | 155,442 | Dec 09 05:03 PM | | LIEPMANN HOLGER A | Executive Vice President | Dec 07 | Sale | 54.25 | 100 | 5,425 | 155,342 | Dec 09 05:03 PM | | Mason Heather L | Senior Vice President | Nov 24 | Option Exercise | 53.60 | 1,384 | 74,182 | 104,653 | Nov 25 05:33 PM | | Mason Heather L | Senior Vice President | Nov 24 | Sale | 54.00 | 1,384 | 74,736 | 103,269 | Nov 25 05:33 PM | | Fussell Stephen R | Senior Vice President | Nov 18 | Option Exercise | 44.30 | 14,892 | 659,752 | 132,892 | Nov 19 06:38 PM | | Fussell Stephen R | Senior Vice President | Nov 18 | Sale | 53.00 | 14,892 | 789,276 | 118,000 | Nov 19 06:38 PM | | Bohuon Olivier | Executive Vice President | Nov 12 | Option Exercise | 45.23 | 70,800 | 3,202,392 | 164,476 | Nov 13 06:21 PM | | Bohuon Olivier | Executive Vice President | Nov 12 | Sale | 53.28 | 90,800 | 4,837,742 | 73,676 | Nov 13 06:21 PM | | Mason Heather L | Senior Vice President | Nov 11 | Option Exercise | 52.45 | 2,152 | 112,878 | 105,421 | Nov 13 06:05 PM | | FREYMAN THOMAS C | Executive Vice President | Nov 11 | Sale | 53.50 | 20,000 | 1,070,000 | 362,515 | Nov 13 06:06 PM | | Mason Heather L | Senior Vice President | Nov 11 | Sale | 53.50 | 2,152 | 115,132 | 103,269 | Nov 13 06:05 PM | | ALBAN CARLOS | Senior Vice President | Nov 02 | Sale | 50.95 | 5,000 | 254,758 | 21,107 | Nov 04 05:05 PM | | Mason Heather L | Senior Vice President | Nov 02 | Sale | 50.92 | 15,000 | 763,814 | 103,269 | Nov 04 05:04 PM | | Patton Donald V JR | Senior Vice President | Oct 26 | Option Exercise | 41.03 | 1,594 | 65,405 | 84,201 | Oct 28 05:07 PM | | ROBERTS ROY S | Director | Oct 20 | Option Exercise | 37.42 | 6,413 | 239,993 | 28,033 | Oct 22 05:06 PM | | Warmuth Michael J | Senior Vice President | Oct 20 | Option Exercise | 41.03 | 7,392 | 303,306 | 76,847 | Oct 22 05:09 PM | | Fussell Stephen R | Senior Vice President | Oct 20 | Sale | 51.81 | 2,977 | 154,242 | 118,000 | Oct 22 05:08 PM | | ROBERTS ROY S | Director | Oct 20 | Sale | 52.04 | 6,413 | 333,717 | 21,620 | Oct 22 05:06 PM | | Patton Donald V JR | Senior Vice President | Oct 16 | Option Exercise | 41.03 | 11,244 | 461,360 | 92,539 | Oct 20 06:06 PM | | Warmuth Michael J | Senior Vice President | Oct 16 | Option Exercise | 41.03 | 4,192 | 172,005 | 73,027 | Oct 20 06:05 PM | | Patton Donald V JR | Senior Vice President | Sep 29 | Option Exercise | 48.10 | 4,290 | 206,349 | 85,585 | Oct 01 05:13 PM | | Patton Donald V JR | Senior Vice President | Sep 29 | Sale | 48.85 | 4,290 | 209,567 | 81,295 | Oct 01 05:13 PM | | Landgraf John C | Senior Vice President | Sep 24 | Sale | 47.00 | 35,000 | 1,645,000 | 85,334 | Sep 25 05:03 PM | | Michael Edward L | Executive Vice President | Sep 01 | Option Exercise | 32.61 | 29,970 | 977,355 | 206,544 | Sep 03 05:05 PM | | Michael Edward L | Executive Vice President | Sep 01 | Sale | 45.00 | 29,970 | 1,348,753 | 176,574 | Sep 03 05:05 PM | | Patton Donald V JR | Senior Vice President | Aug 28 | Option Exercise | 33.23 | 548 | 18,211 | 82,053 | Sep 01 05:20 PM | | Patton Donald V JR | Senior Vice President | Aug 24 | Option Exercise | 33.23 | 3,082 | 102,419 | 83,829 | Aug 26 06:01 PM | | Patton Donald V JR | Senior Vice President | Aug 06 | Sale | 43.81 | 15,000 | 657,153 | 80,747 | Aug 07 05:47 PM | | OSBORN WILLIAM A | Director | May 07 | Buy | 43.15 | 2,000 | 86,300 | 15,382 | May 08 03:01 PM | | Szela Mary T | Senior Vice President | May 01 | Sale | 41.57 | 8,122 | 337,593 | 0 | May 05 05:00 PM | | Patton Donald V JR | Senior Vice President | Apr 22 | Option Exercise | 33.23 | 3,279 | 108,966 | 98,548 | Apr 23 05:52 PM | | Hance Robert B | Senior Vice President | Apr 20 | Sale | 44.19 | 25,000 | 1,104,777 | 136,967 | Apr 22 07:12 PM | | WHITE MILES D | Chairman and CEO | Mar 16 | Sale | 47.50 | 150,000 | 7,125,000 | 1,262,558 | Mar 18 05:04 PM | | Patton Donald V JR | Senior Vice President | Mar 05 | Option Exercise | 33.23 | 4,284 | 142,363 | 100,534 | Mar 09 05:00 PM | | POWELL BOONE JR | Director | Mar 04 | Sale | 46.23 | 3,294 | 152,282 | 27,398 | Mar 05 05:21 PM | | Fussell Stephen R | Senior Vice President | Mar 03 | Sale | 46.26 | 10,000 | 462,564 | 120,977 | Mar 05 05:00 PM | | Schumacher Laura J | Executive Vice President | Feb 27 | Sale | 47.88 | 11,060 | 529,545 | 122,842 | Mar 03 07:26 PM | | Warmuth Michael J | Senior Vice President | Feb 27 | Sale | 48.76 | 434 | 21,163 | 68,153 | Mar 03 07:26 PM | | LIEPMANN HOLGER A | Executive Vice President | Feb 27 | Sale | 47.84 | 10,434 | 499,164 | 155,342 | Mar 03 07:17 PM | | Tyree James L | Executive Vice President | Feb 27 | Sale | 47.68 | 10,454 | 498,458 | 132,176 | Mar 03 07:17 PM | | Mason Heather L | Senior Vice President | Feb 27 | Sale | 48.72 | 578 | 28,161 | 121,679 | Mar 03 08:11 PM | | ABBOTT LABORATORIES | 10% Owner | Feb 26 | Buy | 22.00 | 44,720,768 | 983,856,896 | 103,565,445 | Feb 27 08:36 PM | | LINDER GREG W | Vice President | Feb 25 | Option Exercise | 36.71 | 5,504 | 202,048 | 173,247 | Feb 27 07:34 PM | | ABBOTT LABORATORIES | 10% Owner | Feb 25 | Buy | 22.00 | 56,395,914 | 1,240,710,108 | 58,846,214 | Feb 25 04:28 PM | | TILTON GLENN F | Director | Feb 25 | Buy | 53.63 | 2,000 | 107,260 | 10,647 | Feb 27 07:34 PM | | FULLER H LAURANCE | Director | Feb 18 | Option Exercise | 49.43 | 4,126 | 203,963 | 16,989 | Feb 20 05:39 PM | | Hance Robert B | Senior Vice President | Feb 18 | Sale | 54.35 | 584 | 31,742 | 140,084 | Feb 19 04:31 PM | | FULLER H LAURANCE | Director | Feb 18 | Sale | 53.86 | 4,126 | 222,211 | 12,863 | Feb 20 05:39 PM | | Warmuth Michael J | Senior Vice President | Feb 17 | Sale | 54.37 | 97 | 5,274 | 42,664 | Feb 19 04:30 PM | | Patton Donald V JR | Senior Vice President | Feb 17 | Sale | 54.41 | 417 | 22,690 | 73,026 | Feb 19 04:29 PM | | Mason Heather L | Senior Vice President | Feb 17 | Sale | 54.37 | 417 | 22,673 | 97,177 | Feb 19 04:30 PM | | ASHLEY RICHARD W | Executive Vice President | Feb 17 | Sale | 54.41 | 1,834 | 99,792 | 185,456 | Feb 19 04:30 PM | | FREYMAN THOMAS C | Executive Vice President | Feb 17 | Sale | 54.41 | 954 | 51,909 | 314,075 | Feb 19 04:28 PM | | LINDER GREG W | Vice President | Feb 17 | Sale | 54.45 | 417 | 22,708 | 148,743 | Feb 19 04:28 PM | | Szela Mary T | Senior Vice President | Feb 17 | Sale | 54.40 | 417 | 22,686 | 95,455 | Feb 19 04:29 PM | | Fussell Stephen R | Senior Vice President | Feb 17 | Sale | 54.25 | 884 | 47,959 | 109,552 | Feb 19 08:52 PM | | Schumacher Laura J | Executive Vice President | Feb 17 | Sale | 54.12 | 6,212 | 336,163 | 95,309 | Feb 19 12:18 PM | | Tyree James L | Executive Vice President | Feb 17 | Sale | 54.09 | 5,565 | 301,030 | 103,643 | Feb 19 12:16 PM | | LIEPMANN HOLGER A | Executive Vice President | Feb 17 | Sale | 54.13 | 6,231 | 337,303 | 137,076 | Feb 19 08:54 PM | | Landgraf John C | Senior Vice President | Feb 17 | Sale | 54.44 | 884 | 48,127 | 98,408 | Feb 19 08:57 PM | | LINDER GREG W | Vice President | Feb 09 | Option Exercise | 56.40 | 9,901 | 558,393 | 160,338 | Feb 11 07:43 PM | | Chen Thomas F | Senior Vice President | Feb 09 | Option Exercise | 45.45 | 7,198 | 327,140 | 88,317 | Feb 11 07:35 PM | | LINDER GREG W | Vice President | Feb 09 | Sale | 56.99 | 9,901 | 564,276 | 150,437 | Feb 11 07:43 PM | | Chen Thomas F | Senior Vice President | Feb 06 | Option Exercise | 41.16 | 4,890 | 201,268 | 82,911 | Feb 10 08:26 PM | | Chen Thomas F | Senior Vice President | Feb 06 | Sale | 57.00 | 1,840 | 104,884 | 79,861 | Feb 10 08:26 PM | | Schumacher Laura J | Executive Vice President | Feb 06 | Sale | 57.00 | 37,700 | 2,148,992 | 104,142 | Feb 10 07:48 PM | | Fussell Stephen R | Senior Vice President | Feb 05 | Option Exercise | 56.34 | 11,808 | 665,263 | 125,235 | Feb 09 09:45 PM | | Fussell Stephen R | Senior Vice President | Feb 05 | Sale | 56.44 | 11,808 | 666,444 | 113,427 | Feb 09 09:45 PM | | Fussell Stephen R | Senior Vice President | Feb 04 | Option Exercise | 53.60 | 881 | 47,222 | 114,308 | Feb 06 06:44 PM | | Landgraf John C | Senior Vice President | Feb 04 | Option Exercise | 45.45 | 2,200 | 99,987 | 103,675 | Feb 06 06:19 PM | | FREYMAN THOMAS C | Executive Vice President | Feb 04 | Option Exercise | 52.55 | 20,882 | 1,097,349 | 337,615 | Feb 06 05:40 PM | | Szela Mary T | Senior Vice President | Feb 04 | Option Exercise | 45.45 | 3,445 | 156,571 | 100,096 | Feb 06 05:01 PM | | LIEPMANN HOLGER A | Executive Vice President | Feb 04 | Option Exercise | 45.45 | 1,028 | 46,721 | 146,803 | Feb 06 06:43 PM | | Fussell Stephen R | Senior Vice President | Feb 04 | Sale | 56.25 | 881 | 49,556 | 113,427 | Feb 06 06:44 PM | | Landgraf John C | Senior Vice President | Feb 03 | Option Exercise | 46.90 | 22,252 | 1,043,587 | 112,021 | Feb 05 08:38 PM | | Patton Donald V JR | Senior Vice President | Feb 03 | Option Exercise | 42.41 | 16,206 | 687,347 | 88,511 | Feb 05 07:24 PM | | Szela Mary T | Senior Vice President | Feb 03 | Option Exercise | 54.40 | 2,090 | 113,696 | 98,741 | Feb 05 08:46 PM |
|
|
|
|
|
|
